MTOR and neoplasm: It has been reported that the mammalian target of rapamycin (mTOR) pathway was abnormally activated in NSCLC as evidenced by phosphorylation of mTOR (69%), p70 S6K (81%), and 4EBP-1 (79%) in tumor tissue 8, 9.